Interactions of Polymyxin B in Combination with Aztreonam, Minocycline, Meropenem, and Rifampin against Escherichia coli Producing NDM and OXA-48-Group Carbapenemases
Open Access
- 17 November 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (12), e0106521
- https://doi.org/10.1128/aac.01065-21
Abstract
Carbapenemase-producing Enterobacterales pose an increasing medical threat. Combination therapy is often used for severe infections; however, there is little evidence supporting the optimal selection of drugs. This study aimed to determine the in vitro effects of polymyxin B combinations against carbapenemase-producing Escherichia coli. The interactions of polymyxin B in combination with aztreonam, meropenem, minocycline or rifampin against 20 clinical isolates of NDM and OXA-48-group-producing E. coli were evaluated using time-lapse microscopy; 24-h samples were spotted on plates with and without 4x MIC polymyxin B for viable counts. Whole-genome sequencing was applied to identify resistance genes and mutations. Finally, potential associations between combination effects and bacterial genotypes were assessed using Fisher's exact test. Synergistic and bactericidal effects were observed with polymyxin B and minocycline against 11/20 strains and with polymyxin B and rifampin against 9/20 strains. The combinations of polymyxin B and aztreonam or meropenem showed synergy against 2/20 strains. Negligible resistance development against polymyxin B was detected. Synergy with polymyxin B and minocycline was associated with genes involved in efflux (presence of tet[B], wild-type soxR, and the marB mutation H44Q) and lipopolysaccharide synthesis (eptA C27Y, lpxB mutations, and lpxK L323S). Synergy with polymyxin B and rifampin was associated with sequence variations in arnT, which plays a role in lipid A modification. Polymyxin B in combination with minocycline or rifampin frequently showed positive interactions against NDM- and OXA-48-group-producing E. coli. Synergy was associated with genes encoding efflux and components of the bacterial outer membrane.Funding Information
- AFA Försäkring (180124)
- Joint Programming Initiative on Antimicrobial Resistance (2015-06825)
- Vetenskapsrådet (2019-05911, 2020-02320)
This publication has 29 references indexed in Scilit:
- Assessment of Minocycline and Polymyxin B Combination against Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2015
- Overproduction of AcrR increases organic solvent tolerance mediated by modulation of SoxS regulon in Escherichia coliApplied Microbiology and Biotechnology, 2014
- Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae by In Vitro Time-Kill ExperimentsAntimicrobial Agents and Chemotherapy, 2014
- Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocketNature, 2011
- In Vitro Double and Triple Bactericidal Activities of Doripenem, Polymyxin B, and Rifampin against Multidrug-Resistant Acinetobacter baumannii , Pseudomonas aeruginosa , Klebsiella pneumoniae , and Escherichia coliAntimicrobial Agents and Chemotherapy, 2010
- Single Nucleotide Polymorphism Analysis of the Major Tripartite Multidrug Efflux Pump of Escherichia coli : Functional Conservation in Disparate Animal Reservoirs despite Exposure to Antimicrobial ChemotherapyAntimicrobial Agents and Chemotherapy, 2010
- Crystal Structure of Osmoporin OmpC from E. coli at 2.0 ÅJournal of Molecular Biology, 2006
- Molecular Basis of Bacterial Outer Membrane Permeability RevisitedMicrobiology and Molecular Biology Reviews, 2003
- Substrate Specificity of the RND-Type Multidrug Efflux Pumps AcrB and AcrD of Escherichia coli Is Determined Predominately by Two Large Periplasmic LoopsJournal of Bacteriology, 2002
- Distribution of Core Oligosaccharide Types in Lipopolysaccharides from Escherichia coliInfection and Immunity, 2000